PepGen Inc. (NASDAQ: PEPG) reported results from the 5 mg/kg dose cohort of its Phase 2 FREEDOM2 trial testing PGN-EDODM1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE